Zoran Rankovic

Director of Center for Protein Degradation Institute of Cancer Research

Zoran is a Professor of Chemical Biology and Director of the Centre for Protein Degradation (CPD) at the Institute of Cancer Research (ICR), London. Prior to joining the ICR, Zoran was Director of Chemistry at St Jude Children’s Research Hospital in Memphis, Tennessee, where he established and directed a productive Targeted Protein Degradation program, which developed novel cereblon warheads, PROTACs, and molecular glue clinical candidates. Before St Jude, Zoran was medicinal chemistry director and research fellow in Organon, Schering-Plough, Merck and Eli Lilly. During his over two decades long industrial career Zoran directed teams that delivered multiple clinical candidates over a range of therapeutic areas including oncology, neurodegeneration, psychiatry and cardiovascular disorders. Zoran authored and co-authored over 100 scientific publications, patents, book chapters, and edited two books on drug discovery topics. Zoran’s current research interests focus on expanding and leveraging targeted protein degradation approaches to study cancer biology and develop the next generation of cancer treatments.

Seminars

Thursday 30th October 2025
Panel Discussion: Beyond CRBN & VHL: Harnessing Novel Ligases for Next-Gen Drug Discovery
11:00 am
  • What criteria and validation strategies should be used to determine whether a novel E3 ligase is suitable for therapeutic development?
  • In what ways do novel ligases offer functional or pharmacological advantages over traditional ligases like CRBN or VHL?
  • How can we build a compelling case—biologically and commercially—for prioritizing a novel ligase over established workhorses in drug development pipelines?
Monday 27th October 2025
Multimodal Screening Strategy for Discovery of Novel Cereblon-Directing Molecular Glue Degraders & Neosubstrates
11:30 am
  • Molecular Glue Degrader (MGD) discovery mostly relies on screening-based approaches, such as cell viability assays. However, one limitation of such screening methods is the risk of overlooking non-essential neosubstrates of potential therapeutic value
  • To address this risk, we developed a high throughput deep proteomics screening platform utilizing label-free, data-independent acquisition mass spectrometry for integrated proteomics and “ubiquitinomics” analysis
  • Screening a diverse subset of our large CRBN-focused library uncovered multiple potent and selective degraders of previously unreported cereblon neosubstrates
Thursday 30th October 2025
Chair’s Opening Remarks
9:00 am
Thursday 30th October 2025
Chair’s Closing Remarks
3:30 pm
zoran